Net Income

With a record 21st NMMA CSI Award, Tigé Boats isn't just winning trophies; it's redefining long-term owner loyalty in the competitive marine industry.

With top executives set for major conferences, investors eye Mastercard's playbook for commercial payments and Americas growth amid fierce competition.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

In a strategic move, Central Garden & Pet appoints former exec Kay Schwichtenberg to its board, signaling a focus on animal health and institutional knowledge.

With massive data center orders but cautious guidance, the industrial giant's upcoming conference talks are a key test of investor confidence.

With a 33% revenue surge and expanding margins, Capstone Green Energy's strategic pivot to data centers and EaaS is paying off, marking a major turnaround.

With revolutionary tech and a volatile stock, PureCycle's year-end update is a critical test of its operational progress and financial promises.

Lay's emotional 'Last Harvest' was America's top Super Bowl ad, but a new report reveals a huge generational divide, with Gen Z crowning a different winner.

National Storage Affiliates Trust declared a steady dividend, but a look at its financial performance reveals a complex picture for investors.

A new $7B annual funding plan saves Ontario's colleges and universities but raises tuition and shifts student aid from grants to loans, sparking debt fears.

A new 'longevity center' in Naperville signals a growing trend in proactive health, but what does this mean for the Chicago wellness landscape?

The retail REIT reports record-breaking leasing and strong profits for 2025, while executing a strategic portfolio overhaul and setting a confident tone for 2026.

Despite Q4 headwinds, the auto supplier's massive EV wins and deep focus on China fuel an ambitious 2026 forecast for double-digit profitability.

As Liberty Latin America preps its 2025 results, investors watch to see if strong subscriber growth and cost-cutting can sustain momentum in a competitive market.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

The Midwest bank saw record earnings and shareholder returns in 2025, but a rise in nonperforming loans adds a layer of complexity to its growth story.

Forward Industries' radical crypto pivot is a wild ride. Staking revenue is up 4x, but a market downturn triggered a staggering half-billion-dollar loss.

The pet insurance giant swung to a major profit in 2025, but a closer look reveals a complex strategy of focused growth and rising acquisition costs.